| Literature DB >> 33354921 |
Chuan Huang1, Yaoguang Sun1, Qingjun Wu1, Chao Ma1, Peng Jiao1, Yongzhong Wang1, Wen Huang1, Wenxin Tian1, Hanbo Yu1, Donghang Li1, Hongfeng Tong1.
Abstract
BACKGROUND: The detection rate of bilateral multiple pulmonary nodules (BMPNs) is increasing due to widespread use of chest computed tomography (CT) screening. However, there is no consensus on the treatment options for BMPNs and whether simultaneous bilateral pulmonary resection is safe remains controversial. The purpose of this study was to evaluate the feasibility and safety of simultaneous bilateral pulmonary resection for BMPNs.Entities:
Keywords: Bilateral; multiple pulmonary nodules; single-utility port; video-assisted thoracoscopic surgery
Year: 2020 PMID: 33354921 PMCID: PMC7882384 DOI: 10.1111/1759-7714.13791
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Clinical characteristics and imaging features of 16 patients
| No. | Age (years) | Gender | Smoking index | Comorbidity | Tumor marker | Nodule number (R/L) | Nodule location (R/L) | Maximum diameter (mm) (R/L) | Imaging manifestation (R/L) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 78 | M | 0.1 | HTN | Cyfra21‐1, elevated | 1/1 | RU/LU | 20/40 | SN/SN |
| 2 | 61 | M | 40 | N | Normal | 1/1 | RU/LU | 19/54 | SN/SN |
| 3 | 68 | F | N | HTN/DM/CHD/AF/CI | Normal | 1/1 | RU/LU | 20/13 | pGGO/SN |
| 4 | 64 | F | 90 | HTN | Normal | 1/1 | RU/LU | 13/29 | mGGO/pGGO |
| 5 | 65 | M | 40 | HTN | Normal | 2/1 | RU, RM/LL | 37, 14/15 | SN,SN/SN |
| 6 | 46 | M | 30 | N | CEA, elevated | 1/1 | RU/LL | 10/8 | pGGO/mGGO |
| 7 | 62 | M | 10 | N | Normal | 1/1 | RM/LU | 5/13 | SN/SN |
| 8 | 74 | M | 30 | N | Cyfra21‐1, elevated | 1/1 | RU/LU | 31/26 | SN/SN |
| 9 | 63 | F | N | HTN/Breast cancer | Normal | 1/1 | RL/LU | 6/13 | pGGO/mGGO |
| 10 | 65 | F | N | N | Normal | 1/1 | RU/LL | 10/9 | mGGO/mGGO |
| 11 | 63 | M | 75 | N | Normal | 1/1 | RU/LL | 11/12 | pGGO/mGGO |
| 12 | 64 | M | N | HTN | Normal | 1/1 | RU/LU | 19/15 | mGGO/mGGO |
| 13 | 56 | F | N | HTN | Normal | 1/1 | RU/LL | 15/12 | pGGO/SN |
| 14 | 57 | M | 15 | N | Cyfra21‐1, elevated | 1/2 | RL/LL, LL | 63/12 | SN/SN, SN |
| 15 | 66 | M | N | N | Cyfra21‐1, elevated | 1/2 | RM/LU, LL | 34/12, 5 | mGGO/mGGO, mGGO |
| 16 | 39 | F | N | Thyroid cancer, total thyroidectomy | CA199, elevated | 1/1 | RM/LU | 7/9 | pGGO/pGGO |
AF, atrial fibrillation; CHD, coronary heart disease; CI, cerebral infarction; DM, diabetes mellitus; F, female; HTN, hypertension; L, left; LL, left lower lobe; LU, left upper lobe; M, male; mGGO, mixed ground‐glass opactity; N, no; pGGO, pure ground‐glass opacity; R, right; RL, right lower lobe; RM, right middle lobe; RU, right upper lobe; SN, solid nodule; Y, yes.
Pulmonary function and surgical details of 16 patients
| Pulmonary function | Operation information | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NO. | FEV1 (L) | FEV1 %Pred (%) | MVV (L) | MVV %Pred (%) | DLCO % pred (%) | Resection range (R/L) | Surgical approach (R/L) | Operation time (minutes) | Thoracic drainage duration (days) | Pleural drainage (mL) | Postoperative hospital stay (days) |
| 1 | 2.09 | 85 | 68.49 | 89 | 56 | W/S | V/V | 230 | 2 | 600 | 10 |
| 2 | 2.22 | 67.1 | 66.62 | 54.5 | 84.4 | W/L + S | V/V | 285 | 8 | 2950 | 10 |
| 3 | 2.06 | 83 | 84.81 | 116 | 150 | W/S | V/V | 202 | 4 | 1480 | 7 |
| 4 | 2.01 | 77 | 74.75 | 91 | 137 | L/S | V/V | 230 | 6 | 2380 | 7 |
| 5 | 1.84 | 65 | 51.81 | 51 | 80 | L + W/W | V/V | 315 | 7 | 1550 | 18 |
| 6 | 4.16 | 106.9 | 124.7 | 90 | 86.2 | S/W | V/V | 235 | 5 | 2130 | 6 |
| 7 | 2.56 | 95 | 83.62 | 86 | 98 | W/W | V/V | 65 | 3 | 290 | 5 |
| 8 | 2.19 | 87 | 56.86 | 68 | 82 | L/S | V/V | 315 | 4 | 1870 | 13 |
| 9 | 1.87 | 88 | 64.58 | 76 | 83 | W/L | V/V | 155 | 4 | 1100 | 10 |
| 10 | 1.81 | 101.8 | 54.34 | 69 | 80.8 | S/W | V/V | 170 | 3 | 820 | 5 |
| 11 | 2.1 | 71.3 | 81.94 | 73 | 77.6 | S/S | V/V | 255 | 4 | 1450 | 6 |
| 12 | 2.89 | 97.6 | 74.44 | 66.1 | 75.4 | S/S | V/V | 210 | 4 | 1380 | 7 |
| 13 | 2.53 | 105.3 | 85.79 | 91.9 | 111.8 | S/L | V/V | 215 | 3 | 870 | 6 |
| 14 | 2.27 | 74.8 | 48.43 | 42.2 | 80.5 | L/W | V/V | 160 | 2 | 700 | 6 |
| 15 | 2.99 | 107.6 | 89.61 | 83.4 | 115 | L/S + W | V/V | 190 | 4 | 1250 | 5 |
| 16 | 3.27 | 105.5 | 98.11 | 88.5 | 77.3 | L/S | V/V | 290 | 3 | 1380 | 9 |
DLCO, carbon monoxide diffusing capacity; FEV1, forced expiratory volume in one second; L, lobectomy; MVV, maximal voluntary ventilation; S, segmentectomy; V, video‐assisted thoracoscopic surgery; W, wedge resection.
Figure 1Case 12: A 64‐year‐old male in which preoperative chest CT showed a mixed ground‐glass opacity (GGO) in the apical segment of the right upper lobe (19 × 19 mm) and a mixed GGO in the apicoposterior segment of the left upper lobe (15 × 9 mm). The patient underwent right apical segmentectomy and left apicoposterior segmentectomy via single‐utility port video‐assisted thoracoscopic surgery (VATS). Pathologically, GGO in the right upper lobe was lepidic predominant adenocarcinoma and GGO in the left upper lobe was acinar pattern of adenocarcinoma.
Figure 2Case 15: A 66‐year‐old male in which preoperative chest CT scan showed a mixed ground‐glass opacity (GGO) in the right middle lobe (34 × 20 mm), a mixed GGO in the apicoposterior segment of the left upper lobe (12 × 8 mm), and a mixed GGO in the dorsal segment of the left lower lobe (5 × 3 mm [arrow]). The patient underwent right middle lobectomy, wedge resection of the left upper lobe and left dorsal segmentectomy via single‐utility port video‐assisted thoracoscopic surgery (VATS). Pathologically, GGO in the right middle lobe indicated a papillary pattern of adenocarcinoma, GGO in the left upper lobe minimally invasive adenocarcinoma, and GGO in the left lower lobe atypical adenomatous hyperplasia.
Postoperative outcomes and pathological results of 16 patients
| No. | Postoperative complications | Postoperative pain score and additional analgesics | Pathology (R/L) | VPI (R/L) | LVI (R/L) | pTNM stage (R/L) |
|
|---|---|---|---|---|---|---|---|
| 1 | N | 9/Y | ADC/ADC | N/N | N/N | T1bN0M0, IA2/T2aN0M0, IB | Exon 21 (L858R) |
| 2 | Pulmonary air leakage | 3/N | LPA/70%LCNEC+30%ADC | N/Y | N/Y | T1bN0M0, IA2/T3N0M0, IIB | Exon 21 (L858R) |
| 3 | Atrial fibrillation | 3/N | LPA/85%LPA + 10%PPA + 5%MPA | Y/N | N/N | T2aN0M0, IB/T1bN0M0, IA2 | Exon 19 deletion |
| 4 | N | 7/Y | 60%APA + 30%LPA + 10%MPA/LPA | N/N | N/N | T1aN0M0, IA1/T1cN0M0, IA3 | Exon 21 (L858R) |
| 5 | Poor healing of surgical site | 9/Y | 70%APA + 20%PPA + 10%SPA, Benign/benign | N/N | N/N | T1bN0M0, IA2/− | Exon 21 (L858R) |
| 6 | N | 10/Y | AIS/AIS | N/N | N/N | TisN0M0/TisN0M0 | Negative |
| 7 | N | 3/N | Benign/hamartoma | N/N | N/N | — | None |
| 8 | N | 8/Y | ASC/ASC | N/N | Y/N | T2aN0M0, IB/T1cN0M0, IA3 | Negative |
| 9 | N | 8/Y | Benign/60%PPA + 30%LPA + 10%APA | N/N | N/N | –/T1bN0M0, IA2 | Negative |
| 10 | N | 8/Y | MIA/80%APA + 20%LPA | N/N | N/N | T1aN0M0, IA1/T1aN0M0, IA1 | Negative |
| 11 | N | 3/N | APA/70%LPA + 30%APA | N/N | N/N | T1aN0M0, IA1/T1bN0M0, IA2 | Negative |
| 12 | N | 3/N | LPA/APA | N/N | N/N | T1bN0M0, IA2/T1bN0M0, IA2 | Exon 19 deletion |
| 13 | N | 8/Y | LPA/60%PPA + 40%APA | N/Y | N/N | T1bN0M0, IA2/T2aN0M0, IB | Exon 19 deletion |
| 14 | N | 2/N | SCC/Benign, benign | N/N | Y/N | T3N0M0, IIB/− | None |
| 15 | N | 2/N | 60%PPA + 30%LPA + 10%APA/MIA, AAH | N/N | N/N | T1bN0M0, IA2/T1AN0M0, IA1 | Exon 19 deletion |
| 16 | N | 2/N | 80%LPA + 20%APA/80%LPA + 20%APA | N/N | N/N | T1aN0M0, IA1/T1aN0M0, IA1 | Negative |
AAH, atypical adenomatous hyperplasia; ADC, adenocarcinoma; AIS, adenocarcinoma in situ; APA, acinar pattern of adenocarcinoma; ASC, adenosquamous carcinoma; Be, benign; Ha, hamartoma; LCNEC, large cell neuroendocrine carcinoma; LPA, lepidic predominant adenocarcinoma; LVI, lymphovascular invasion; MIA, minimally invasive adenocarcinoma; MPA, micropalillary pattern of adenocarcinoma; N, no; PPA, papillary pattern of adenocarcinoma; pTNM, pathological tumor node metastasis; SCC, squamous cell carcinoma; SPA, solid pattern of adenocarcinoma; VPI, visceral pleural invasion; Y, yes.